Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  International Journal of Biochemistry and Cell Biology

• Publication date

  2014-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.biocel.2014.04.019PMID 24796845PMCID PMC4111967
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

  2014cited by this paper
• Peptide-based anticancer vaccines

  2013cited by this paper
• Antigen depots: T cell traps?

  2013cited by this paper
• Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells

  2013cited by this paper
• Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment.

  2013cited by this paper
• CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2

  2013cited by this paper
• Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer.

  2013cited by this paper
• Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion

  2013cited by this paper
• Ways to Enhance Lymphocyte Trafficking into Tumors and Fitness of Tumor Infiltrating Lymphocytes

  2013cited by this paper
• Targeting TNF-α to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy

  2012cited by this paper
• Immune tolerance to tumor antigens occurs in a specialized environment of the spleen.

  2012cited by this paper
• Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies

  2011cited by this paper
• Cancer immunotherapy comes of age

  2011cited by this paper
• gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

  2011cited by this paper
• The parallel lives of angiogenesis and immunosuppression: cancer and other tales

  2011cited by this paper
• Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment.

  2011cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Transduction of Tumor-Specific T Cells with CXCR2 Chemokine Receptor Improves Migration to Tumor and Antitumor Immune Responses

  2010cited by this paper
• Gene-expression profiling in vaccine therapy and immunotherapy for cancer

  2010cited by this paper
• Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.

  2009cited by this paper
• Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment.

  2009cited by this paper
• Myeloid-derived suppressor cells as regulators of the immune system

  2009cited by this paper
• Cancer immunotherapy by dendritic cells.

  2008cited by this paper
• Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

  2008cited by this paper
• Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy

  2008cited by this paper
• Superior induction of anti‐tumor CTL immunity by extended peptide vaccines involves prolonged, DC‐focused antigen presentation

  2008cited by this paper
• Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell–dendritic cell interaction

  2006cited by this paper
• CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors

  2006cited by this paper
• Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity.

  2006cited by this paper
• Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma

  2005cited by this paper
• Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

  2005cited by this paper
• Cancer immunotherapy: moving beyond current vaccines

  2004cited by this paper
• Combined TLR and CD40 Triggering Induces Potent CD8+ T Cell Expansion with Variable Dependence on Type I IFN

  2004cited by this paper
• Cancer and the chemokine network

  2004cited by this paper
• Preferential Accumulation of Antigen-specific Effector CD4 T Cells at an Antigen Injection Site Involves CD62E-dependent Migration but Not Local Proliferation

  2003cited by this paper
• Established Human Papillomavirus Type 16-Expressing Tumors Are Effectively Eradicated Following Vaccination with Long Peptides1

  2002cited by this paper
• CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy

  1999cited by this paper

• Standardization of Antigen-Emulsion Preparations for the Induction of Autoimmune Disease Models

  2022cites this paper
• Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial

  2021cites this paper
• Adenine-Based Purines and Related Metabolizing Enzymes: Evidence for Their Impact on Tumor Extracellular Vesicle Activities

  2021cites this paper
• Immune Responses and Antitumor Effect through Delivering to Antigen Presenting Cells by Optimized Conjugates Consisting of CpG-DNA and Antigenic Peptide.

  2020cites this paper
• Fundamentals of Cancer Immunology and Their Application to Cancer Vaccines

  2020cites this paper
• Targeting Angiogenesis With Peptide Vaccines

  2019cites this paper
• Infection Prevention: Oil- and Lipid-Containing Products in Vaccinology

  2018cites this paper
• Virus-Specific CD8+ T Cells Infiltrate Melanoma Lesions and Retain Function Independently of PD-1 Expression

  2017cites this paper
• A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer

  2017cites this paper
• CpG oligodeoxynucleotides augment antitumor efficacy of folate receptor α based DNA vaccine.

  2017cites this paper
• Independently of PD-1 Expression Melanoma Lesions and Retain Function T Cells Infiltrate + Virus-Specific CD 8

  2017cites this paper
• Identifying and targeting immunogenic mutations in ovarian cancer

  2016influential citation
• Intratumoral Infection with Murine Cytomegalovirus Synergizes with PD-L1 Blockade to Clear Melanoma Lesions and Induce Long-term Immunity.

  2016cites this paper
• Construction , expression and purification of recombinant HBcAg-MAGE-A 3 therapeutic cancer vaccine

  2016cites this paper
• Blocking IL-10 signalling at the time of immunization renders the tumour more accessible to T cell infiltration in mice.

  2016cites this paper
• Anti–PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM

  2016cites this paper
• Flagellin is a strong vaginal adjuvant of a therapeutic vaccine for genital cancer

  2015cites this paper
• Assessment of immunological responses to tumour antigens relevant to the development of therapeutic cancer vaccines

  2015cites this paper
• CURRENT UNDERSTANDING OF ANTITUMOR IMMUNITY

  2015cites this paper